Pfizer, Valneva Report Positive Lyme Disease Vaccine Candidate Data
By Michael Susin
Pfizer and Valneva on Tuesday said data from a mid-stage study regarding the second booster dose from its Lyme disease vaccine candidate showed positive results.
The companies said the phase 2 study of the VLA15-221 vaccine showed a strong immune response and positive safety profile one month after the second booster dose.
The response is consistent to those reported after receiving the first booster dose, they said, showing the compatibility with the anticipated benefit of a booster vaccination prior to each Lyme season.
Pfizer and Valneva added that the VLA15 vaccine is currently undergoing phase 3 trials, adding that there currently isn't an approved human vaccine for Lyme disease.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
September 03, 2024 06:28 ET (10:28 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
United States